Humacyte, a pioneering brand in regenerative medicine, is revolutionizing the field with their innovative biotechnology platform. They specialize in developing off-the-shelf, bioengineered human tissues and organs that can be universally implanted. Their flagship product, the Humacyte Human Acellular Vessel (HAV), is currently in clinical trials for various vascular applications, such as vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.

Beyond these applications, Humacyte's platform technology holds immense potential for complex organ diseases. This includes creating bioengineered replacement tissues and organs for coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes. Founded in 2004 by Dr.

Laura Niklason, a renowned leader in tissue engineering, and her esteemed colleagues, Humacyte is dedicated to improving and saving the lives of patients worldwide. Located in Durham, North Carolina, the company is committed to bringing first-in-class regenerative medicine products to the market, ushering in a new era of medical practice